Foreign Companies Advancing Cell Therapies in Japan
Lee Buckler,
Vice President ,
RepliCel Life Sciences
Japan’s new regenerative medicine legislation provides foreign cell therapy companies with a pathway to achieve conditional approval and bring their product to market more quickly than anywhere else in the world. This presentation explains Japan’s regenerative medicine policy reform, the promotion act, changes and benefits of their new conditional approval system and the steps foreign companies may take to establish a leadership position.
|
|
